← 產業報告目錄

Biosurgery Market by Product (Bone Graft Substitutes, Sealants (Natural (Gelatin, Collagen)), Hemostatic Agents, Soft-tissue Attachments (Synthetic, Biological)), Application (Orthopedic, Urological), End User (Hospitals, ASCs) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-07-28頁數 414報告編號 MD3554

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global biosurgery market is projected to reach USD 21.59 million by 2030 from USD 15.83 million in 2025, at a CAGR of 6.4% during the forecast period. The biosurgery market is experiencing robust growth, propelled by several key dynamics. A primary driver is the increasing prevalence of chronic conditions that necessitate surgical interventions, alongside a rise in severe traumatic injuries. As these incidents become more common, there is a corresponding uptick in the volume of elective surgical procedures, subsequently fueling the demand for biosurgical products. Moreover, the escalating need for efficient blood loss management and the enhanced availability of advanced biosurgical technologies further support market expansion. However, this growth trajectory faces challenges, including the high cost associated with biosurgery products, a shortage of adequately skilled professionals, and a stringent regulatory environment, all of which are anticipated to hinder the market's progress over the forecast period. The demineralized bone matrix subsegment, by bone graft substitutes, held the largest market share in 2024. Based on product, the biosurgery market is divided into bone-graft substitutes, soft-tissue attachments, hemostatic agents, surgical sealants and adhesives, adhesion barriers, and staple-line reinforcement agents. In 2024, the bone graft substitute market was predominantly led by the demineralized bone matrix (DBM) segment, which is recognized for its dual osteoconductive and osteoinductive properties, thereby facilitating effective bone regeneration. Within the broader category of bone graft substitutes—which includes synthetic grafts, bone morphogenetic proteins (BMPs), and other alternatives—DBM has emerged as the most significant player in the biosurgery sector. DBM is extensively employed in various orthopedic procedures, such as spinal fusion and hip & knee replacements, owing to its enhanced clinical efficacy in promoting bone healing. Its versatility is further accentuated by its availability in multiple forms, including pastes, putty, sheets, and flexible fragments, allowing for tailored surgical applications. The process of creating DBM involves the removal of inorganic minerals from allograft bones, which unveils BMPs that actively stimulate osteogenesis. This characteristic positions DBM as a reliable and biologically active substitute for autografts. Furthermore, implementing terminal sterilization techniques, such as gamma irradiation and electron-beam sterilization, ensures the safety and integrity of the product. The sustained preference of surgeons for DBM as a safe, effective, and accessible graft substitute continues to reinforce its leading status within this market segment. The ambulatory surgical centers of the biosurgery end user market are expected to command the highest CAGR during the study period. The biosurgery market, based on end users, is divided into ambulatory surgical centers (ASCs), hospitals, clinics, and other end users. The ambulatory surgical centers (ASCs) segment is anticipated to lead growth in the biosurgery market throughout the forecast period. This expansion is underpinned by an increasing demand for cost-effective, efficient, and minimally invasive surgical options. ASCs present an economically viable alternative to traditional hospitals while upholding high standards for surgical safety and clinical outcomes, making them increasingly appealing to patients and healthcare practitioners. These centers are optimally equipped to perform various outpatient procedures, including orthopedic, ophthalmic, cosmetic, and general surgeries. In these settings, biosurgical products such as sealants, hemostats, and adhesion barriers are critical in enhancing surgical precision and promoting patient recovery. Advancements in surgical techniques, anesthesia, and biosurgical technologies accelerate the ongoing transition of surgical volumes from inpatient environments to outpatient facilities. Factors such as rising healthcare expenditures, advantageous reimbursement policies for outpatient procedures, and reduced patient recovery times are further driving the growth of ASCs. As patient preferences increasingly lean toward expedited, same-day procedures with a minimized risk of hospital-acquired infections, the demand for biosurgical solutions in ASCs is projected to escalate, thus propelling rapid growth in this segment. In 2024, the North America region accounted for the largest share in the biosurgery market. The global biosurgery market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2024, the North American region is projected to maintain the largest share of the global biosurgery market, attributable to its sophisticated healthcare infrastructure, elevated surgical rates, and the concentration of prominent industry players. This region has experienced notable increases in cosmetic and reconstructive surgeries and a marked rise in orthopedic procedures. According to Discovery ABA, approximately 26.2 million surgical and minimally invasive cosmetic and reconstructive procedures were performed in the United States in 2022, reflecting a 19% increase in cosmetic surgeries compared to 2019. Furthermore, the 2022 data from the American Joint Replacement Registry (AJRR) highlights over 2.8 million hip and knee procedures conducted across all 50 states and the District of Columbia, underscoring the significant demand for biosurgery products in joint replacement and orthopedic applications. Key drivers for this market expansion include a growing geriatric population, a high incidence of chronic diseases, and an increasing volume of surgical interventions necessitating advanced hemostatic agents, sealants, and materials for soft tissue repair. Coupled with favorable reimbursement frameworks, heightened patient awareness, and substantial R&D investments from leading companies such as Johnson & Johnson, Baxter, and Stryker, North America is solidifying its position as the most dominant and mature biosurgery market globally. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1- 40%, Tier 2- 30%, and Tier 3- 30% • By Designation: C-level- 50%, Director level- 30%, and Others- 20% • By Region: North America- 30%, Europe- 25%, Asia Pacific- 20%, Latin America- 15%, and Middle East & Africa- 10%. Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.0 billion, Tier 2 = USD 1.0 billion to USD 10.0 billion, and Tier 3 = <USD 1.0 billion. Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs. Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers. The players operating in the biosurgery market include Johnson & Johnson Services, Inc. (US), Baxter (US), Medtronic (Ireland), Becton, Dickinson and Company (BD) (US), B. Braun Melsungen AG (Germany), Stryker (US), Integra Lifesciences Holdings Corporation (US), CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Artivion Inc. (US), Zimmer Biomet (US), Kuros Biosciences AG (Switzerland), Orthofix Medical Inc. (US), Smiths & Nephew PLC (UK), Tissue Regenix (UK), Betatech Medical (Turkey), Meril Lifesciences Pvt. Ltd. (India), RTI Surgicals (US), Samyang Holdings Corp. (South Korea), Aroa Biosurgery Ltd. (New Zealand), Meyer-Haake GmbH (Germany), Advanced Medical Solutions Group PLC (UK), BioCer Entwicklungs-GmbH (Germany), and Hannox International Corp. (Taiwan) Research Coverage This report studies the biosurgery market based on product, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets concerning their growth trends. It forecasts the revenue of the market segments concerning five major regions (and the respective countries in these regions). Reasons to Buy the Report The report will enable established and entrants/smaller firms to gauge the market's pulse, which, in turn, would help them gain a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence. This report provides insights on the following pointers: • Analysis of key drivers (increasing volume of surgeries and growing prevalence of severe trauma injuries, strong focus on R&D leading to launch of technologically advanced products, and rising need for effective blood loss management in patients), restraints (high price of biosurgery products and rising cost of surgical procedures), opportunities (increasing use of combination materials for enhancing product efficacy, rising adoption of advanced biosurgery products in emerging markets, and growing adoption of adhesive dentistry procedures), challenges (stringent regulatory framework and requirement of skilled personnel for the effective use of biosurgery products) • Market Penetration: Complete knowledge of the spectrum of products presented by the major companies in the biosurgery market • Product Development/Innovation: Comprehensive understanding of the forthcoming trends, R&D initiatives, and product launches within the biosurgery market • Market Development: Complete knowledge about profitable developing regions • Market Diversification: Exhaustive knowledge of new goods, expanding geographies, and current changes in the biosurgery industry help to diversify the market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Johnson & Johnson Services, Inc. (US), Baxter (US), Medtronic (Ireland), Becton Dickinson and Company (BD) (US), B. Braun SE (Germany), Stryker (US), Integra LifeSciences Holdings Corporation (US), CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Artivion Inc. (US), and others.
目錄 Table of Contents
1 INTRODUCTION 36 1.1 STUDY OBJECTIVES 36 1.2 MARKET DEFINITION 36 1.3 STUDY SCOPE 37 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 37 1.3.2 INCLUSIONS & EXCLUSIONS 38 1.3.3 YEARS CONSIDERED 39 1.3.4 CURRENCY CONSIDERED 40 1.4 STAKEHOLDERS 40 1.5 SUMMARY OF CHANGES 41 2 RESEARCH METHODOLOGY 42 2.1 RESEARCH DATA 42 2.1.1 SECONDARY DATA 42 2.1.1.1 Key objectives of secondary research 43 2.1.1.2 List of key secondary sources 43 2.1.1.3 Key data from secondary sources 44 2.1.2 PRIMARY DATA 44 2.1.2.1 Key objectives of primary research 45 2.1.2.2 Key data from primary sources 46 2.1.2.3 Key industry insights 47 2.2 MARKET SIZE ESTIMATION 48 2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 48 2.2.2 TOP-DOWN APPROACH 49 2.2.3 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 49 2.2.4 GROWTH FORECAST 49 2.3 DATA TRIANGULATION 52 2.4 MARKET RANKING ANALYSIS 52 2.5 STUDY ASSUMPTIONS 53 2.6 RESEARCH LIMITATIONS 53 2.6.1 METHODOLOGY-RELATED LIMITATIONS 53 2.6.2 SCOPE-RELATED LIMITATIONS 53 2.7 RISK ANALYSIS 54 3 EXECUTIVE SUMMARY 55   4 PREMIUM INSIGHTS 59 4.1 BIOSURGERY MARKET OVERVIEW 59 4.2 NORTH AMERICA: BIOSURGERY MARKET, BY COUNTRY AND END USER 60 4.3 GEOGRAPHIC SNAPSHOT OF BIOSURGERY MARKET 61 4.4 REGIONAL MIX: BIOSURGERY MARKET, 2025–2030 (USD MILLION) 61 4.5 BIOSURGERY MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2030 (USD MILLION) 62 5 MARKET OVERVIEW 63 5.1 INTRODUCTION 63 5.2 MARKET DYNAMICS 63 5.2.1 DRIVERS 64 5.2.1.1 Increasing volume of surgeries and growing prevalence of severe trauma injuries 64 5.2.1.2 Rising need for effective blood loss management 64 5.2.2 RESTRAINTS 64 5.2.2.1 High price of biosurgery products and surgical procedures 64 5.2.3 OPPORTUNITIES 65 5.2.3.1 Rising use of combination materials for enhancing product efficacy 65 5.2.3.2 Growing adoption of adhesive dentistry procedures 65 5.2.4 CHALLENGES 65 5.2.4.1 Stringent regulatory framework 65 5.2.4.2 Scarcity of skilled personnel for effective use of biosurgery products 66 5.3 TECHNOLOGY ANALYSIS 66 5.3.1 KEY TECHNOLOGIES 66 5.3.1.1 Hemostatic & sealant biomaterial technology 66 5.3.1.2 Tissue engineering & regenerative medicine technology 67 5.3.2 COMPLEMENTARY TECHNOLOGIES 67 5.3.2.1 Surgical imaging & navigation technology 67 5.3.2.2 Sterilization & preservation technology 67 5.3.3 ADJACENT TECHNOLOGIES 68 5.3.3.1 3D printing technology 68 5.3.3.2 Minimally invasive technology 68 5.4 INDUSTRY TRENDS 68 5.4.1 GROWING PREFERENCE FOR GELATIN-BASED ADHESIVES & HYDROGELS IN SURGICAL PROCEDURES 68 5.4.2 USE OF NANOTECHNOLOGY FOR DEVELOPING NEXT-GENERATION ADHESIVES 69 5.5 VALUE CHAIN ANALYSIS 69 5.6 ECOSYSTEM ANALYSIS 70 5.7 SUPPLY CHAIN ANALYSIS 71 5.8 TRADE ANALYSIS 72 5.8.1 IMPORT DATA FOR HS CODE 300610, 2019–2024 72 5.8.2 EXPORT DATA FOR HS CODE 300610, 2019–2024 72 5.9 PORTER’S FIVE FORCES ANALYSIS 73 5.9.1 THREAT OF NEW ENTRANTS 74 5.9.2 THREAT OF SUBSTITUTES 74 5.9.3 BARGAINING POWER OF BUYERS 75 5.9.4 BARGAINING POWER OF SUPPLIERS 75 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 75 5.10 KEY STAKEHOLDERS & BUYING CRITERIA 75 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 75 5.10.2 KEY BUYING CRITERIA 76 5.11 REGULATORY ANALYSIS 77 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 5.11.2 REGULATORY ANALYSIS 80 5.11.2.1 North America 80 5.11.2.1.1 US 80 5.11.2.1.2 Canada 80 5.11.2.2 Europe 81 5.11.2.3 Asia Pacific 81 5.11.2.4 Latin America 82 5.11.2.5 Middle East & Africa 82 5.12 PATENT ANALYSIS 82 5.12.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 84 5.13 PRICING ANALYSIS 84 5.13.1 AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY KEY PLAYER, 2022–2024 84 5.13.2 AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY REGION, 2022–2024 85 5.14 KEY CONFERENCES & EVENTS, 2025–2026 86 5.15 ADJACENT MARKET ANALYSIS 87 5.15.1 ADHESION BARRIERS MARKET 87 5.16 UNMET NEEDS/END-USER EXPECTATIONS 88 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 89 5.18 INVESTMENT & FUNDING SCENARIO 89 5.19 IMPACT OF AI/GEN AI ON BIOSURGERY MARKET 90 5.20 IMPACT OF 2025 US TARIFF ON BIOSURGERY MARKET 91 5.20.1 INTRODUCTION 91 5.20.2 KEY TARIFF RATES 92 5.20.3 PRICE IMPACT ANALYSIS 93 5.20.4 IMPACT ON COUNTRIES/REGIONS 93 5.20.4.1 North America 93 5.20.4.1.1 US 93   5.20.4.2 Europe 94 5.20.4.3 Asia Pacific 94 5.20.5 IMPACT ON END-USE INDUSTRIES 94 6 BIOSURGERY MARKET, BY PRODUCT 95 6.1 INTRODUCTION 96 6.2 BONE-GRAFT SUBSTITUTES 97 6.2.1 DEMINERALIZED BONE MATRIX 98 6.2.1.1 Rising volume of spinal fusion, joint reconstruction, and replacement surgeries to drive segment 98 6.2.2 SYNTHETIC BONE GRAFTS 100 6.2.2.1 High compressive strength, osteoconductive properties, and minimal risk of disease transmission to fuel segment growth 100 6.2.3 BONE MORPHOGENETIC PROTEINS 102 6.2.3.1 Increasing prevalence of spinal deformities, disc degeneration, trauma, and sport-related injuries to propel segment growth 102 6.2.4 OTHER BONE-GRAFT SUBSTITUTES 103 6.3 SURGICAL SEALANTS & ADHESIVES 105 6.3.1 NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES 107 6.3.1.1 Natural/Biological surgical sealants & adhesives, by type 108 6.3.1.1.1 Fibrin-based sealants & adhesives 109 6.3.1.1.1.1 Biocompatibility, biodegradability, and effectiveness in achieving hemostasis to augment segment growth 109 6.3.1.1.2 Collagen-based sealants & adhesives 111 6.3.1.1.2.1 Low-cost and reduced risk of disease transmission to promote adoption of collagen-based sealants & adhesives 111 6.3.1.1.3 Gelatin-based sealants & adhesives 113 6.3.1.1.3.1 High elasticity, strong adhesive properties, and versatility in soft tissue applications to boost segment growth 113 6.3.1.1.4 Albumin-based sealants & adhesives 115 6.3.1.1.4.1 Increasing adoption in cardiovascular and cardiothoracic procedures to fuel market growth 115 6.3.1.1.5 Other natural/biological surgical sealants & adhesives 116 6.3.1.2 Natural/biological surgical sealants & adhesives, by origin 118 6.3.1.2.1 Animal-based sealants & adhesives 118 6.3.1.2.1.1 Ease of usage, better flexibility, and greater strength to boost adoption in medical applications 118 6.3.1.2.2 Human blood-based sealants & adhesives 119 6.3.1.2.2.1 Human blood-based sealants to be used in final stage of clotting cascade for local and diffused hemorrhages 119 6.3.2 SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES 120 6.3.2.1 PEG hydrogel-based sealants & adhesives 123 6.3.2.1.1 Rapid sealing abilities of PEG hydrogels to drive adoption in spinal surgeries 123   6.3.2.2 Cyanoacrylate-based sealants & adhesives 125 6.3.2.2.1 Cyanoacrylate-based sealants to be preferred in dermatology and plastic surgeries 125 6.3.2.3 Urethane-based sealants & adhesives 126 6.3.2.3.1 Favorable thermostable property at body temperature without hemolytic behavior to drive segment 126 6.3.2.4 Other synthetic & semi-synthetic surgical sealants & adhesives 128 6.4 ADHESION BARRIERS 129 6.4.1 SYNTHETIC ADHESION BARRIERS 131 6.4.1.1 Hyaluronic acid-based adhesion barriers 133 6.4.1.1.1 Rising gynecological and abdominal surgeries to fuel adoption 133 6.4.1.2 Regenerated cellulose-based adhesion barriers 134 6.4.1.2.1 Increasing number of C-section surgeries to boost adoption of regenerated cellulose-based adhesion barriers 134 6.4.1.3 PEG-based adhesion barriers 136 6.4.1.3.1 Rising number of peritoneal and abdominal surgeries to drive demand 136 6.4.1.4 Other synthetic adhesion barriers 137 6.4.2 NATURAL ADHESION BARRIERS 138 6.4.2.1 Collagen & protein adhesion barriers 139 6.4.2.1.1 Weak antigenicity, high biocompatibility, non-toxicity, and biodegradability to propel segment growth 139 6.4.2.2 Fibrin-based adhesion barriers 140 6.4.2.2.1 Increasing applications in laparotomy procedures to spur segment growth 140 6.5 STAPLE-LINE REINFORCEMENT AGENTS 142 6.5.1 RISING VOLUME OF COMPLEX SURGICAL PROCEDURRES TO DRIVE MARKET 142 6.6 SOFT-TISSUE ATTACHMENTS 143 6.6.1 SYNTHETIC MESHES 145 6.6.1.1 Increasing demand for safe and cost-effective soft tissue reinforcement to drive segment 145 6.6.2 BIOLOGICAL MESHES 146 6.6.2.1 Allografts 148 6.6.2.1.1 Rising cancer incidence and reconstructive surgeries to increase adoption of allografts in biosurgical procedures 148 6.6.2.2 Xenografts 149 6.6.2.2.1 High availability and size versatility to drive segmental growth 149 6.7 HEMOSTATIC AGENTS 150 6.7.1 THROMBIN-BASED HEMOSTATIC AGENTS 152 6.7.1.1 Rising demand for safer and fast-acting clotting agents to drive growth of thrombin-based hemostats 152 6.7.2 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS 154 6.7.2.1 Rising adoption of plant-based and absorbable hemostats to propel segment growth 154 6.7.3 COMBINATION HEMOSTATIC AGENTS 155 6.7.3.1 Superior efficacy in complex bleeding control to drive adoption of combination hemostatic agents globally 155 7 BIOSURGERY MARKET, BY APPLICATION 157 7.1 INTRODUCTION 158 7.2 ORTHOPEDIC SURGERY 158 7.2.1 INCREASING INCIDENCE OF SPORTS INJURIES AND GROWING PREVALENCE OF OSTEOPOROSIS TO PROPEL MARKET GROWTH 158 7.3 GENERAL SURGERY 160 7.3.1 HIGH GERIATRIC POPULATION AND INCREASED PREVALENCE OF OBESITY TO FUEL DEMAND FOR BARIATRIC INTERVENTIONS 160 7.4 NEUROLOGICAL SURGERY 162 7.4.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO AUGMENT MARKET GROWTH 162 7.5 CARDIOVASCULAR SURGERY 163 7.5.1 BIOSURGERY PRODUCTS TO REPLACE CONVENTIONAL SUTURE-BASED METHODS IN CARDIOVASCULAR PROCEDURES 163 7.6 RECONSTRUCTIVE SURGERY 165 7.6.1 INCREASING FACIAL COSMETIC SURGERIES AND BREAST RECONSTRUCTION PROCEDURES TO PROPEL MARKET GROWTH 165 7.7 GYNECOLOGICAL SURGERY 166 7.7.1 COMPLEXITY OF GYNECOLOGICAL PROCEDURES TO FUEL DEMAND FOR ADVANCED BIOSURGICAL PRODUCTS 166 7.8 UROLOGICAL SURGERY 168 7.8.1 USE OF BIOSURGERY PRODUCTS IN COMPLEX RECONSTRUCTIVE UROLOGICAL SURGERIES TO STIMULATE SEGMENT GROWTH 168 7.9 THORACIC SURGERY 169 7.9.1 RISING INCIDENCE OF PULMONARY CHRONIC DISEASES TO SPUR MARKET GROWTH 169 7.10 OTHER APPLICATIONS 171 8 BIOSURGERY MARKET, BY END USER 173 8.1 INTRODUCTION 174 8.2 HOSPITALS 174 8.2.1 RISING NUMBER OF REIMBURSED INPATIENT PROCEDURES TO DRIVE POPULARITY OF HOSPITALS FOR SURGERIES 174 8.3 CLINICS 176 8.3.1 QUICKER CONSULTATION SERVICES AND MINIMAL PATIENT STAYS TO FAVOR MARKET GROWTH 176 8.4 AMBULATORY SURGICAL CENTERS 177 8.4.1 RISING DEMAND FOR COST-EFFECTIVE SAME-DAY SURGERIES TO AUGMENT MARKET GROWTH 177 8.5 OTHER END USERS 178   9 BIOSURGERY MARKET, BY REGION 180 9.1 INTRODUCTION 181 9.2 NORTH AMERICA 182 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 182 9.2.2 US 189 9.2.2.1 US to dominate North American biosurgery market during forecast period 189 9.2.3 CANADA 195 9.2.3.1 Growing prevalence of chronic diseases to drive market 195 9.3 EUROPE 201 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 207 9.3.2 GERMANY 207 9.3.2.1 Robust healthcare investments and improved infrastructure to support adoption of advanced surgical technologies 207 9.3.3 UK 213 9.3.3.1 Rise in popularity of cosmetic and reconstructive surgeries to fuel market growth 213 9.3.4 FRANCE 219 9.3.4.1 Presence of well-established healthcare system and high geriatric population to boost market growth 219 9.3.5 ITALY 225 9.3.5.1 Increasing surgical volume to fuel market growth 225 9.3.6 SPAIN 231 9.3.6.1 Rising surgical demand to boost need for biosurgery products 231 9.3.7 REST OF EUROPE 237 9.4 ASIA PACIFIC 243 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 243 9.4.2 CHINA 251 9.4.2.1 Increasing number of domestic biosurgery and medical device manufacturers to aid market growth 251 9.4.3 INDIA 257 9.4.3.1 Rising healthcare awareness and favorable government support to stimulate market growth 257 9.4.4 JAPAN 263 9.4.4.1 Advanced healthcare system and high geriatric population to spur market growth 263 9.4.5 SOUTH KOREA 269 9.4.5.1 Rising number of cosmetic surgeries and growing adoption of innovative medical technologies to drive market 269 9.4.6 AUSTRALIA 275 9.4.6.1 Well-established healthcare system and high government medical expenditure to favor market growth 275 9.4.7 REST OF ASIA PACIFIC 281   9.5 LATIN AMERICA 288 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 288 9.5.2 BRAZIL 294 9.5.2.1 Rapidly aging population and high prevalence of chronic diseases to support market growth 294 9.5.3 MEXICO 300 9.5.3.1 Enhanced focus on medical tourism to drive market 300 9.5.4 REST OF LATIN AMERICA 306 9.6 MIDDLE EAST & AFRICA 313 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 313 9.6.2 GCC COUNTRIES 319 9.6.2.1 Rising prevalence of chronic diseases to drive market 319 9.6.3 REST OF MIDDLE EAST & AFRICA 325 10 COMPETITIVE LANDSCAPE 332 10.1 INTRODUCTION 332 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 332 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSURGERY MARKET 332 10.3 REVENUE ANALYSIS, 2020–2024 334 10.4 MARKET SHARE ANALYSIS, 2024 334 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 336 10.5.1 STARS 336 10.5.2 EMERGING LEADERS 336 10.5.3 PERVASIVE PLAYERS 337 10.5.4 PARTICIPANTS 337 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 338 10.5.5.1 Company footprint 338 10.5.5.2 Region footprint 339 10.5.5.3 Product footprint 340 10.5.5.4 Application footprint 341 10.5.5.5 End-user footprint 342 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 343 10.6.1 PROGRESSIVE COMPANIES 343 10.6.2 RESPONSIVE COMPANIES 343 10.6.3 DYNAMIC COMPANIES 343 10.6.4 STARTING BLOCKS 343 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 345 10.6.5.1 Detailed list of key startups/SMEs 345 10.6.5.2 Competitive benchmarking of key startups/SMEs 346 10.7 COMPANY VALUATION & FINANCIAL METRICS 347 10.7.1 FINANCIAL METRICS 347 10.7.2 COMPANY VALUATION 347 10.8 BRAND/PRODUCT COMPARISON 348 10.9 COMPETITIVE SCENARIO 348 10.9.1 PRODUCT LAUNCHES & APPROVALS 348 10.9.2 DEALS 349 11 COMPANY PROFILES 350 11.1 KEY PLAYERS 350 11.1.1 BAXTER 350 11.1.1.1 Business overview 350 11.1.1.2 Products offered 351 11.1.1.3 MnM view 352 11.1.1.3.1 Key strengths 352 11.1.1.3.2 Strategic choices 353 11.1.1.3.3 Weaknesses & competitive threats 353 11.1.2 B. BRAUN SE 354 11.1.2.1 Business overview 354 11.1.2.2 Products offered 355 11.1.2.3 MnM view 356 11.1.2.3.1 Key strengths 356 11.1.2.3.2 Strategic choices 356 11.1.2.3.3 Weaknesses & competitive threats 356 11.1.3 BECTON, DICKINSON AND COMPANY (BD) 357 11.1.3.1 Business overview 357 11.1.3.2 Products offered 358 11.1.3.3 MnM view 360 11.1.3.3.1 Key strengths 360 11.1.3.3.2 Strategic choices 360 11.1.3.3.3 Weaknesses & competitive threats 360 11.1.4 JOHNSON & JOHNSON 361 11.1.4.1 Business overview 361 11.1.4.2 Products offered 362 11.1.4.3 MnM view 363 11.1.4.3.1 Key strengths 363 11.1.4.3.2 Strategic choices 363 11.1.4.3.3 Weaknesses & competitive threats 364 11.1.5 MEDTRONIC 365 11.1.5.1 Business overview 365 11.1.5.2 Products offered 366 11.1.5.3 MnM view 367 11.1.5.3.1 Key strengths 367 11.1.5.3.2 Strategic choices 367 11.1.5.3.3 Weaknesses & competitive threats 368 11.1.6 INTEGRA LIFESCIENCES CORPORATION 369 11.1.6.1 Business overview 369 11.1.6.2 Products offered 370 11.1.7 COMMONWEALTH SERUM LABORATORIES LIMITED (CSL) 372 11.1.7.1 Business overview 372 11.1.7.2 Products offered 373 11.1.8 HEMOSTASIS, LLC 374 11.1.8.1 Business overview 374 11.1.8.2 Products offered 374 11.1.9 PFIZER INC. 375 11.1.9.1 Business overview 375 11.1.9.2 Products offered 376 11.1.10 STRYKER 377 11.1.10.1 Business overview 377 11.1.10.2 Products offered 378 11.1.11 ARTIVION, INC. 380 11.1.11.1 Business overview 380 11.1.11.2 Products offered 381 11.1.12 ZIMMER BIOMET 383 11.1.12.1 Business overview 383 11.1.12.2 Products offered 384 11.1.12.3 Recent developments 385 11.1.12.3.1 Deals 385 11.1.13 KUROS BIOSCIENCES 386 11.1.13.1 Business overview 386 11.1.13.2 Products offered 387 11.1.13.3 Recent developments 387 11.1.13.3.1 Product approvals 387 11.1.13.3.2 Deals 388 11.1.14 ORTHOFIX MEDICAL INC. 389 11.1.14.1 Business overview 389 11.1.14.2 Products offered 390 11.1.14.3 Recent developments 391 11.1.14.3.1 Product launches 391 11.1.14.3.2 Deals 391 11.1.15 SMITH & NEPHEW 392 11.1.15.1 Business overview 392 11.1.15.2 Products offered 393 11.2 OTHER PLAYERS 394 11.2.1 TISSUE REGENIX 394 11.2.2 BETATECH MEDICAL 395 11.2.3 MERIL LIFE SCIENCES PVT. LTD. 396 11.2.4 GLOBUS MEDICAL 397 11.2.5 SAMYANG HOLDINGS CORPORATION 398 11.2.6 AROA BIOSURGERY LIMITED 399 11.2.7 MEYER-HAAKE GMBH 400 11.2.8 ADVANCED MEDICAL SOLUTIONS GROUP PLC 401 11.2.9 BIOCER ENTWICKLUNGS-GMBH 402 11.2.10 WILTROM 403 12 APPENDIX 404 12.1 DISCUSSION GUIDE 404 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 410 12.3 CUSTOMIZATION OPTIONS 412 12.4 RELATED REPORTS 412 12.5 AUTHOR DETAILS 413
圖表清單 List of Tables & Figures
TABLE 1 BIOSURGERY MARKET: INCLUSIONS & EXCLUSIONS 38 TABLE 2 STANDARD CURRENCY CONVERSION RATES 40 TABLE 3 BIOSURGERY MARKET: STUDY ASSUMPTIONS 53 TABLE 4 BIOSURGERY MARKET: RISK ANALYSIS 54 TABLE 5 IMPORT DATA FOR HS CODE 300610, BY COUNTRY, 2019–2024 (USD THOUSAND) 72 TABLE 6 EXPORT DATA FOR HS CODE 300610, BY COUNTRY, 2019–2024 (USD THOUSAND) 73 TABLE 7 BIOSURGERY MARKET: PORTER’S FIVE FORCES 73 TABLE 8 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE BIOSURGERY PRODUCTS 76 TABLE 9 KEY BUYING CRITERIA FOR BIOSURGERY PRODUCTS 77 TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 15 AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 85 TABLE 16 AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY REGION, 2022–2024 (USD) 85 TABLE 17 BIOSURGERY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 86 TABLE 18 BIOSURGERY MARKET: UNMET NEEDS/END-USER EXPECTATIONS 88 TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 92 TABLE 20 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR BIOSURGERY PRODUCTS 93 TABLE 21 BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 96 TABLE 22 BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 97 TABLE 23 BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 24 MAJOR DEMINERALIZED BONE MATRIX PRODUCTS AVAILABLE IN MARKET 99 TABLE 25 DEMINERALIZED BONE MATRIX MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 26 MAJOR SYNTHETIC BONE GRAFTS AVAILABLE IN MARKET 101 TABLE 27 SYNTHETIC BONE GRAFTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 28 MAJOR BONE MORPHOGENETIC PROTEINS AVAILABLE IN MARKET 102 TABLE 29 BONE MORPHOGENETIC PROTEINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 30 OTHER BONE-GRAFT SUBSTITUTES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 31 BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 106 TABLE 32 BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 33 NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 108 TABLE 34 NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 35 MAJOR FIBRIN-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET 110 TABLE 36 FIBRIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 37 MAJOR COLLAGEN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET 112 TABLE 38 COLLEGEN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 39 MAJOR GELATIN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET 114 TABLE 40 GELATIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 41 MAJOR ALBUMIN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET 115 TABLE 42 ALBUMIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 43 OTHER NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 44 NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 118 TABLE 45 ANIMAL-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 46 HUMAN BLOOD-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 47 SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 121 TABLE 48 SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 49 MAJOR PRODUCTS PEG HYDROGEL-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET 123 TABLE 50 PEG HYROGEL-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 51 MAJOR CYANOACRYLATE-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET 125 TABLE 52 CYANOACRYLATE-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 53 URETHANE-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 54 OTHER SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 55 BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 130 TABLE 56 BIOSURGERY MARKET FOR ADHESION BARRIERS, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 57 SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 131 TABLE 58 SYNTHETIC ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 59 MAJOR HYALURONIC ACID-BASED ADHESION BARRIERS AVAILABLE IN MARKET 133 TABLE 60 HYALURONIC ACID-BASED ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 61 MAJOR REGENERATED CELLULOSE-BASED ADHESION BARRIERS AVAILABLE IN MARKET 135 TABLE 62 REGENERATED CELLULOSE -BASED ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 63 MAJOR PEG-BASED ADHESION BARRIERS AVAILABLE IN MARKET 136 TABLE 64 PEG-BASED ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 65 OTHER SYNTHETIC ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 66 NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 139 TABLE 67 MAJOR COLLAGEN & PROTEIN ADHESION BARRIERS AVAILABLE IN MARKET 139 TABLE 68 COLLAGEN & PROTEIN ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 69 MAJOR FIBRIN-BASED ADHESION BARRIERS AVAILABLE IN MARKET 141 TABLE 70 FIBRIN-BASED ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 71 MAJOR STAPLE-LINE REINFORCEMENT AGENTS AVAILABLE IN MARKET 142 TABLE 72 BIOSURGERY MARKET FOR STAPLE-LINE REINFORCEMENT AGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 73 BIOSURGERY MARKET FOR SOFT-TISSUE ATTCHMENTS, BY TYPE, 2023–2030 (USD MILLION) 144 TABLE 74 BIOSURGERY MARKET FOR SOFT-TISSUE ATTCHMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 75 MAJOR SYNTHETIC MESHES AVAILABLE IN MARKET 145 TABLE 76 SYNTHETIC MESHES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 77 MAJOR BIOLOGICAL MESHES AVAILABLE IN MARKET 147 TABLE 78 BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 147 TABLE 79 BIOLOGICAL MESHES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 80 ALLOGRAFTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 81 XENOGRAFTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 82 MAJOR HEMOSTATIC AGENTS AVAILABLE IN MARKET 151 TABLE 83 BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 151 TABLE 84 BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 85 MAJOR THROMBIN-BASED HEMOSTATIC AGENTS AVAILABLE IN MARKET 153 TABLE 86 THROMBIN-BASED HEMOSTATIC AGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 87 MAJOR OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS AVAILABLE IN MARKET 154 TABLE 88 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 89 MAJOR COMBINATION HEMOSTATIC AGENTS AVAILABLE IN MARKET 156 TABLE 90 COMBINATION HEMOSTATIC AGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 91 BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 158 TABLE 92 BIOSURGERY MARKET FOR ORTHOPEDIC SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 93 BIOSURGERY MARKET FOR GENERAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 94 BIOSURGERY MARKET FOR NEUROLOGICAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 95 BIOSURGERY MARKET FOR CARDIOVASCULAR SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 96 BIOSURGERY MARKET FOR RECONSTRUCTIVE SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 97 BIOSURGERY MARKET FOR GYNECOLOGICAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 98 BIOSURGERY MARKET FOR UROLOGICAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 99 BIOSURGERY MARKET FOR THORACIC SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 100 BIOSURGERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 101 BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 174 TABLE 102 BIOSURGERY MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 103 BIOSURGERY MARKET FOR CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 104 BIOSURGERY MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 105 BIOSURGERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 106 BIOSURGERY MARKET, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 107 NORTH AMERICA: BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 108 NORTH AMERICA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 184 TABLE 109 NORTH AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 110 NORTH AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 185 TABLE 111 NORTH AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 185 TABLE 112 NORTH AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 186 TABLE 113 NORTH AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 114 NORTH AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 115 NORTH AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 187 TABLE 116 NORTH AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 187 TABLE 117 NORTH AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 187 TABLE 118 NORTH AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 119 NORTH AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 120 NORTH AMERICA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 188 TABLE 121 NORTH AMERICA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 189 TABLE 122 US: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 190 TABLE 123 US: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 190 TABLE 124 US: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 191 TABLE 125 US: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 191 TABLE 126 US: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 192 TABLE 127 US: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 192 TABLE 128 US: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 192 TABLE 129 US: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 130 US: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 131 US: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 132 US: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 194 TABLE 133 US: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 194 TABLE 134 US: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 194 TABLE 135 US: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 195 TABLE 136 CANADA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 195 TABLE 137 CANADA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 138 CANADA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 139 CANADA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 197 TABLE 140 CANADA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 197 TABLE 141 CANADA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 142 CANADA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 143 CANADA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 144 CANADA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 199 TABLE 145 CANADA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 199 TABLE 146 CANADA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 199 TABLE 147 CANADA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 200 TABLE 148 CANADA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 200 TABLE 149 CANADA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 201 TABLE 150 EUROPE: BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 151 EUROPE: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 202 TABLE 152 EUROPE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 202 TABLE 153 EUROPE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 203 TABLE 154 EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 203 TABLE 155 EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 204 TABLE 156 EUROPE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 204 TABLE 157 EUROPE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 204 TABLE 158 EUROPE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 159 EUROPE: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 160 EUROPE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 161 EUROPE: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 206 TABLE 162 EUROPE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 206 TABLE 163 EUROPE: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 206 TABLE 164 EUROPE: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 207 TABLE 165 GERMANY: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 208 TABLE 166 GERMANY: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 167 GERMANY: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 168 GERMANY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 209 TABLE 169 GERMANY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 209 TABLE 170 GERMANY: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 210 TABLE 171 GERMANY: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 210 TABLE 172 GERMANY: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 210 TABLE 173 GERMANY: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 174 GERMANY: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 175 GERMANY: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 176 GERMANY: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 212 TABLE 177 GERMANY: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 212 TABLE 178 GERMANY: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 213 TABLE 179 UK: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 213 TABLE 180 UK: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 181 UK: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 182 UK: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 215 TABLE 183 UK: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 215 TABLE 184 UK: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 216 TABLE 185 UK: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 216 TABLE 186 UK: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 216 TABLE 187 UK: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 217 TABLE 188 UK: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 217 TABLE 189 UK: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 217 TABLE 190 UK: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 218 TABLE 191 UK: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 218 TABLE 192 UK: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 219 TABLE 193 FRANCE: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 219 TABLE 194 FRANCE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 195 FRANCE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 196 FRANCE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 197 FRANCE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 221 TABLE 198 FRANCE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 199 FRANCE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 200 FRANCE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 201 FRANCE: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 223 TABLE 202 FRANCE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 223 TABLE 203 FRANCE: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 223 TABLE 204 FRANCE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 205 FRANCE: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 224 TABLE 206 FRANCE: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 225 TABLE 207 ITALY: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 225 TABLE 208 ITALY: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 226 TABLE 209 ITALY: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 226 TABLE 210 ITALY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 211 ITALY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 227 TABLE 212 ITALY: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 213 ITALY: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 214 ITALY: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 215 ITALY: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 216 ITALY: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 217 ITALY: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 218 ITALY: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 219 ITALY: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 230 TABLE 220 ITALY: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 231 TABLE 221 SPAIN: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 231 TABLE 222 SPAIN: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 223 SPAIN: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 224 SPAIN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 225 SPAIN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 233 TABLE 226 SPAIN: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 234 TABLE 227 SPAIN: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 234 TABLE 228 SPAIN: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 229 SPAIN: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 230 SPAIN: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 231 SPAIN: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 232 SPAIN: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 233 SPAIN: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 236 TABLE 234 SPAIN: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 237 TABLE 235 REST OF EUROPE: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 237 TABLE 236 REST OF EUROPE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 237 REST OF EUROPE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 238 REST OF EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 239 REST OF EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 239 TABLE 240 REST OF EUROPE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 241 REST OF EUROPE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 242 REST OF EUROPE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 243 REST OF EUROPE: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 244 REST OF EUROPE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 245 REST OF EUROPE: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 246 REST OF EUROPE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 247 REST OF EUROPE: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 242 TABLE 248 REST OF EUROPE: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 243 TABLE 249 ASIA PACIFIC: BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 245 TABLE 250 ASIA PACIFIC: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 245 TABLE 251 ASIA PACIFIC: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 252 ASIA PACIFIC: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 253 ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 254 ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 247 TABLE 255 ASIA PACIFIC: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 256 ASIA PACIFIC: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 257 ASIA PACIFIC: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 258 ASIA PACIFIC: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 259 ASIA PACIFIC: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 260 ASIA PACIFIC: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 250 TABLE 261 ASIA PACIFIC: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 250 TABLE 262 ASIA PACIFIC: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 250 TABLE 263 ASIA PACIFIC: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 251 TABLE 264 CHINA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 252 TABLE 265 CHINA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 266 CHINA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 267 CHINA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 268 CHINA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 253 TABLE 269 CHINA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 270 CHINA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 271 CHINA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 272 CHINA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 273 CHINA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 274 CHINA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 275 CHINA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 276 CHINA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 256 TABLE 277 CHINA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 257 TABLE 278 INDIA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 257 TABLE 279 INDIA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 280 INDIA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 281 INDIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 282 INDIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 259 TABLE 283 INDIA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 284 INDIA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 285 INDIA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 286 INDIA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 287 INDIA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 288 INDIA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 289 INDIA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 290 INDIA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 262 TABLE 291 INDIA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 263 TABLE 292 JAPAN: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 263 TABLE 293 JAPAN: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 294 JAPAN: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 295 JAPAN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 296 JAPAN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 265 TABLE 297 JAPAN: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 266 TABLE 298 JAPAN: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 266 TABLE 299 JAPAN: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 266 TABLE 300 JAPAN: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 301 JAPAN: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 302 JAPAN: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 303 JAPAN: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 304 JAPAN: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 268 TABLE 305 JAPAN: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 269 TABLE 306 SOUTH KOREA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 269 TABLE 307 SOUTH KOREA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 270 TABLE 308 SOUTH KOREA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 270 TABLE 309 SOUTH KOREA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 271 TABLE 310 SOUTH KOREA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 271 TABLE 311 SOUTH KOREA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 312 SOUTH KOREA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 313 SOUTH KOREA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 314 SOUTH KOREA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 315 SOUTH KOREA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 316 SOUTH KOREA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 317 SOUTH KOREA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 318 SOUTH KOREA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 274 TABLE 319 SOUTH KOREA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 275 TABLE 320 AUSTRALIA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 275 TABLE 321 AUSTRALIA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 276 TABLE 322 AUSTRALIA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 276 TABLE 323 AUSTRALIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 277 TABLE 324 AUSTRALIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 277 TABLE 325 AUSTRALIA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 326 AUSTRALIA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 327 AUSTRALIA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 328 AUSTRALIA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 329 AUSTRALIA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 330 AUSTRALIA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 331 AUSTRALIA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 280 TABLE 332 AUSTRALIA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 280 TABLE 333 AUSTRALIA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 281 TABLE 334 REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 281 TABLE 335 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 336 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 337 REST OF ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 283 TABLE 338 REST OF ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 283 TABLE 339 REST OF ASIA PACIFIC: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 340 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 284 TABLE 341 REST OF ASIA PACIFIC: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 342 REST OF ASIA PACIFIC: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 343 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 344 REST OF ASIA PACIFIC: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 345 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 346 REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 287 TABLE 347 REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 287 TABLE 348 LATIN AMERICA: BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 288 TABLE 349 LATIN AMERICA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 289 TABLE 350 LATIN AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 289 TABLE 351 LATIN AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 290 TABLE 352 LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 290 TABLE 353 LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 291 TABLE 354 LATIN AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 355 LATIN AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 356 LATIN AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 357 LATIN AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 358 LATIN AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 292 TABLE 359 LATIN AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 360 LATIN AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 361 LATIN AMERICA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 293 TABLE 362 LATIN AMERICA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 294 TABLE 363 BRAZIL: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 294 TABLE 364 BRAZIL: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 295 TABLE 365 BRAZIL: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 295 TABLE 366 BRAZIL: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 367 BRAZIL: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 296 TABLE 368 BRAZIL: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 297 TABLE 369 BRAZIL: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 297 TABLE 370 BRAZIL: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 371 BRAZIL: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 372 BRAZIL: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 298 TABLE 373 BRAZIL: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 299 TABLE 374 BRAZIL: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 299 TABLE 375 BRAZIL: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 299 TABLE 376 BRAZIL: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 300 TABLE 377 MEXICO: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 300 TABLE 378 MEXICO: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 379 MEXICO: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 380 MEXICO: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 302 TABLE 381 MEXICO: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 302 TABLE 382 MEXICO: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 383 MEXICO: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 384 MEXICO: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 385 MEXICO: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 386 MEXICO: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 387 MEXICO: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 388 MEXICO: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 305 TABLE 389 MEXICO: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 305 TABLE 390 MEXICO: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 306 TABLE 391 REST OF LATIN AMERICA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 306 TABLE 392 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 393 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 394 REST OF LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 395 REST OF LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 308 TABLE 396 REST OF LATIN AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 397 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 309 TABLE 398 REST OF LATIN AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 399 REST OF LATIN AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 400 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 401 REST OF LATIN AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 311 TABLE 402 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 311 TABLE 403 REST OF LATIN AMERICA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 312 TABLE 404 REST OF LATIN AMERICA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 312 TABLE 405 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY REGION, 2023–2030 (USD MILLION) 313 TABLE 406 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 314 TABLE 407 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 314 TABLE 408 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 409 MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 410 MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 316 TABLE 411 MIDDLE EAST & AFRICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 316 TABLE 412 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 316 TABLE 413 MIDDLE EAST & AFRICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 414 MIDDLE EAST & AFRICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 415 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 416 MIDDLE EAST & AFRICA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 417 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 418 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 319 TABLE 419 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 319 TABLE 420 GCC COUNTRIES: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 320 TABLE 421 GCC COUNTRIES: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 320 TABLE 422 GCC COUNTRIES: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 321 TABLE 423 GCC COUNTRIES: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 321 TABLE 424 GCC COUNTRIES: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 322 TABLE 425 GCC COUNTRIES: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 426 GCC COUNTRIES: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 427 GCC COUNTRIES: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 428 GCC COUNTRIES: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 429 GCC COUNTRIES: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 323 TABLE 430 GCC COUNTRIES: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 431 GCC COUNTRIES: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 432 GCC COUNTRIES: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 324 TABLE 433 GCC COUNTRIES: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 325 TABLE 434 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 325 TABLE 435 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 326 TABLE 436 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 326 TABLE 437 REST OF MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 327 TABLE 438 REST OF MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION) 327 TABLE 439 REST OF MIDDLE EAST & AFRICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION) 328 TABLE 440 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION) 328 TABLE 441 REST OF MIDDLE EAST & AFRICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 442 REST OF MIDDLE EAST & AFRICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 443 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 444 REST OF MIDDLE EAST & AFRICA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 445 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION) 330 TABLE 446 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 331 TABLE 447 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 331 TABLE 448 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN BIOSURGERY MARKET 332 TABLE 449 BIOSURGERY MARKET: DEGREE OF COMPETITION 335 TABLE 450 BIOSURGERY MARKET: REGION FOOTPRINT 339 TABLE 451 BIOSURGERY MARKET: PRODUCT FOOTPRINT 340 TABLE 452 BIOSURGERY MARKET: APPLICATION FOOTPRINT 341 TABLE 453 BIOSURGERY MARKET: END-USER FOOTPRINT 342 TABLE 454 BIOSURGERY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 345 TABLE 455 BIOSURGERY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT AND REGION 346 TABLE 456 BIOSURGERY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 348 TABLE 457 BIOSURGERY MARKET: DEALS, JANUARY 2022–JUNE 2025 349 TABLE 458 BAXTER: COMPANY OVERVIEW 350 TABLE 459 BAXTER: PRODUCTS OFFERED 351 TABLE 460 B BRAUN SE: COMPANY OVERVIEW 354 TABLE 461 B BRAUN SE: PRODUCTS OFFERED 355 TABLE 462 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 357 TABLE 463 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 358 TABLE 464 JOHNSON & JOHNSON: COMPANY OVERVIEW 361 TABLE 465 JOHNSON & JOHNSON: PRODUCTS OFFERED 362 TABLE 466 MEDTRONIC: COMPANY OVERVIEW 365 TABLE 467 MEDTRONIC: PRODUCTS OFFERED 366 TABLE 468 INTEGRA LIFESCIENCES CORPORATION: COMPANY OVERVIEW 369 TABLE 469 INTEGRA LIFESCIENCES CORPORATION: PRODUCTS OFFERED 370 TABLE 470 COMMONWEALTH SERUM LABORATORIES LIMITED (CSL): COMPANY OVERVIEW 372 TABLE 471 COMMONWEALTH SERUM LABORATORIES LIMITED (CSL): PRODUCTS OFFERED 373 TABLE 472 HEMOSTASIS, LLC: COMPANY OVERVIEW 374 TABLE 473 HEMOSTASIS, LLC: PRODUCTS OFFERED 374 TABLE 474 PFIZER INC.: COMPANY OVERVIEW 375 TABLE 475 PFIZER INC.: PRODUCTS OFFERED 376 TABLE 476 STRYKER: COMPANY OVERVIEW 377 TABLE 477 STRYKER: PRODUCTS OFFERED 378 TABLE 478 ARTIVION, INC.: COMPANY OVERVIEW 380 TABLE 479 ARTIVION, INC.: PRODUCTS OFFERED 381 TABLE 480 ZIMMER BIOMET: COMPANY OVERVIEW 383 TABLE 481 ZIMMER BIOMET: PRODUCTS OFFERED 384 TABLE 482 ZIMMER BIOMET: DEALS, JANUARY 2022–JUNE 2025 385 TABLE 483 KUROS BIOSCIENCES: COMPANY OVERVIEW 386 TABLE 484 KUROS BIOSCIENCES: PRODUCTS OFFERED 387 TABLE 485 KUROS BIOSCIENCES: PRODUCT APPROVALS, JANUARY 2021–JUNE 2025 387 TABLE 486 KUROS BIOSCIENCES: DEALS, JANUARY 2022–JUNE 2025 388 TABLE 487 ORTHOFIX MEDICAL INC.: COMPANY OVERVIEW 389 TABLE 488 ORTHOFIX MEDICAL INC.: PRODUCTS OFFERED 390 TABLE 489 ORTHOFIX MEDICAL INC.: PRODUCT LAUNCHES, JANUARY 2021–JUNE 2025 391 TABLE 490 ORTHOFIX MEDICAL INC.: DEALS, JANUARY 2022–JUNE 2025 391 TABLE 491 SMITH & NEPHEW: COMPANY OVERVIEW 392 TABLE 492 SMITH & NEPHEW: PRODUCTS OFFERED 393 TABLE 493 TISSUE REGENIX: COMPANY OVERVIEW 394 TABLE 494 BETATECH MEDICAL: COMPANY OVERVIEW 395 TABLE 495 MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW 396 TABLE 496 GLOBUS MEDICAL: COMPANY OVERVIEW 397 TABLE 497 SAMYANG HOLDINGS CORPORATION: COMPANY OVERVIEW 398 TABLE 498 AROA BIOSURGERY LIMITED: COMPANY OVERVIEW 399 TABLE 499 MEYER-HAAKE GMBH: COMPANY OVERVIEW 400 TABLE 500 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY OVERVIEW 401 TABLE 501 BIOCER ENTWICKLUNGS-GMBH: COMPANY OVERVIEW 402 TABLE 502 WILTROM: COMPANY OVERVIEW 403 FIGURE 1 BIOSURGERY MARKET SEGMENTATION & REGIONAL SCOPE 37 FIGURE 2 BIOSURGERY MARKET: YEARS CONSIDERED 39 FIGURE 3 BIOSURGERY MARKET: RESEARCH DESIGN 42 FIGURE 4 BIOSURGERY MARKET: KEY DATA FROM SECONDARY SOURCES 44 FIGURE 5 BIOSURGERY MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDES) 45 FIGURE 6 BIOSURGERY MARKET: KEY DATA FROM PRIMARY SOURCES 46 FIGURE 7 BIOSURGERY MARKET: KEY INDUSTRY INSIGHTS 47 FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 47 FIGURE 9 BIOSURGERY MARKET SIZE ESTIMATION (REVENUE SHARE ANALYSIS) 48 FIGURE 10 BIOSURGERY MARKET: TOP-DOWN APPROACH 49 FIGURE 11 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030) 50 FIGURE 12 BIOSURGERY MARKET: CAGR PROJECTIONS 50 FIGURE 13 BIOSURGERY MARKET: DATA TRIANGULATION METHODOLOGY 52 FIGURE 14 BIOSURGERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 55 FIGURE 15 BIOSURGERY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 56 FIGURE 16 BIOSURGERY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 57 FIGURE 17 BIOSURGERY MARKET: REGIONAL SNAPSHOT 58 FIGURE 18 RISING SURGICAL VOLUMES AND INCREASING FOCUS ON MEDICAL TOURISM TO DRIVE MARKET 59 FIGURE 19 US AND HOSPITALS SEGMENT COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024 60 FIGURE 20 INDIA TO WITNESS HIGHEST CAGR DURING STUDY PERIOD 61 FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE FROM 2025 TO 2030 61 FIGURE 22 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 62 FIGURE 23 BIOSURGERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63 FIGURE 24 BIOSURGERY MARKET: VALUE CHAIN ANALYSIS 70 FIGURE 25 BIOSURGERY MARKET: ECOSYSTEM ANALYSIS 70 FIGURE 26 BIOSURGERY MARKET: SUPPLY CHAIN ANALYSIS 71 FIGURE 27 BIOSURGERY MARKET: PORTER’S FIVE FORCES ANALYSIS 74 FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF TOP THREE BIOSURGERY PRODUCTS 76 FIGURE 29 KEY BUYING CRITERIA FOR BIOSURGERY PRODUCTS 77 FIGURE 30 CANADA: CLASS III MEDICAL DEVICE APPROVAL PROCESS 81 FIGURE 31 TOP 10 COMPANIES WITH HIGHEST NUMBER OF PATENTS APPLIED/PUBLISHED (JANUARY 2014–JUNE 2025) 83 FIGURE 32 TOP APPLICANT COUNTRIES/REGIONS FOR BIOSURGERY PATENTS (JANUARY 2014− MAY 2025) 84 FIGURE 33 ADJACENT MARKET ANALYSIS: ADHESION BARRIERS MARKET (MARKET OVERVIEW) 87 FIGURE 34 BIOSURGERY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 89 FIGURE 35 BIOSURGERY MARKET: FUNDING AND NUMBER OF DEALS, 2019–2023 (USD MILLION) 89 FIGURE 36 KEY FEATURES OF AI/GEN AI IN BIOSURGERY MARKET 91 FIGURE 37 BIOSURGERY MARKET: GEOGRAPHIC SNAPSHOT 181 FIGURE 38 NORTH AMERICA: BIOSURGERY MARKET SNAPSHOT 183 FIGURE 39 ASIA PACIFIC: BIOSURGERY MARKET SNAPSHOT 244 FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN BIOSURGERY MARKET (2020–2024) 334 FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOSURGERY MARKET (2024) 335 FIGURE 42 BIOSURGERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 337 FIGURE 43 BIOSURGERY MARKET: COMPANY FOOTPRINT 338 FIGURE 44 BIOSURGERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 344 FIGURE 45 EV/EBITDA OF KEY VENDORS 347 FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 347 FIGURE 47 BIOSURGERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 348 FIGURE 48 BAXTER: COMPANY SNAPSHOT 351 FIGURE 49 B BRAUN SE: COMPANY SNAPSHOT 355 FIGURE 50 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT 358 FIGURE 51 JOHNSON & JOHNSON: COMPANY SNAPSHOT 362 FIGURE 52 MEDTRONIC: COMPANY SNAPSHOT 366 FIGURE 53 INTEGRA LIFESCIENCES CORPORATION: COMPANY SNAPSHOT 370 FIGURE 54 COMMONWEALTH SERUM LABORATORIES LIMITED (CSL): COMPANY SNAPSHOT 373 FIGURE 55 PFIZER INC.: COMPANY SNAPSHOT 376 FIGURE 56 STRYKER: COMPANY SNAPSHOT 378 FIGURE 57 ARTIVION, INC.: COMPANY SNAPSHOT 381 FIGURE 58 ZIMMER BIOMET: COMPANY SNAPSHOT 384 FIGURE 59 KUROS BIOSCIENCES: COMPANY SNAPSHOT 386 FIGURE 60 ORTHOFIX MEDICAL INC.: COMPANY SNAPSHOT 390 FIGURE 61 SMITH & NEPHEW: COMPANY SNAPSHOT 393

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們